These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25399725)

  • 1. Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.
    Perrier L; Buja A; Mastrangelo G; Baron PS; Ducimetière F; Pauwels PJ; Rossi CR; Gilly FN; Martin A; Favier B; Farsi F; Laramas M; Baldo V; Collard O; Cellier D; Blay JY; Ray-Coquard I
    BMC Health Serv Res; 2014 Nov; 14():537. PubMed ID: 25399725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.
    Pöhlmann J; Norrbacka K; Boye KS; Valentine WJ; Sapin H
    Eur J Health Econ; 2020 Nov; 21(8):1179-1196. PubMed ID: 33025257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can economic evaluations be made more transferable?
    Boulenger S; Nixon J; Drummond M; Ulmann P; Rice S; de Pouvourville G
    Eur J Health Econ; 2005 Dec; 6(4):334-46. PubMed ID: 16249933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries.
    Badia JM; Casey AL; Petrosillo N; Hudson PM; Mitchell SA; Crosby C
    J Hosp Infect; 2017 May; 96(1):1-15. PubMed ID: 28410761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
    Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methodology of economic assessment: example in oncology].
    Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
    Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of breast cancer based on real-world data: a cancer registry study in Italy.
    Capri S; Russo A
    BMC Health Serv Res; 2017 Jan; 17(1):84. PubMed ID: 28122558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
    Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
    Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis.
    Liao M; Li Y; Kianifard F; Obi E; Arcona S
    BMC Nephrol; 2016 Mar; 17():25. PubMed ID: 26936756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for completing the EURONHEED transferability information checklists.
    Nixon J; Rice S; Drummond M; Boulenger S; Ulmann P; de Pouvourville G
    Eur J Health Econ; 2009 May; 10(2):157-65. PubMed ID: 18618158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision chart for assessing and improving the transferability of economic evaluation results between countries.
    Welte R; Feenstra T; Jager H; Leidl R
    Pharmacoeconomics; 2004; 22(13):857-76. PubMed ID: 15329031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries.
    Boehler CE; Lord J
    Med Decis Making; 2016 Jan; 36(1):31-47. PubMed ID: 25878194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interest in and limitations of economic assessment applied to the evaluation of medical strategies: examples in oncological hematology].
    Moatti JP
    Therapie; 2001; 56(2):135-8. PubMed ID: 11471364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review.
    Ruggeri M; Manca A; Coretti S; Codella P; Iacopino V; Romano F; Mascia D; Orlando V; Cicchetti A
    Value Health; 2015 Jul; 18(5):709-20. PubMed ID: 26297100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of cancer treatment costs: another tool for oncology managers.
    Chirikos TN; Ruckdeschel JC; Krischer JP
    J Oncol Manag; 2001; 10(3):11-7. PubMed ID: 11548179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
    Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
    J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer: we do need primary cost data.
    Bonastre J; Jan P; Barthe Y; Koscielny S
    Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.